CR
Capital Research Global Investors disclosed a 8.2% stake in ALNY
Capital Research Global Investors reported owning 8.2% of Alnylam Pharmaceuticals, Inc. (ALNY) (10,940,905 shares) in a Schedule 13G filed Nov 13, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 13, 2026
- Source
- Schedule 13G